DahlhausSHoepnerRChanA. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry2013; 84: 1068–1074.
2.
BloomgrenGRichmanSHotermansC. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med2012; 366: 1870–1880.
3.
GorelikLLernerMBixlerS. Anti-JC virus antibodies: Implications for PML risk stratification. Ann Neurol. 2010; 68: 295–303.
4.
TrampeAKHemmelmannCStroetA. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology2012; 78: 1736–1742.
5.
LeePPlavinaTCastroA. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol2013; 57: 141–146.
6.
OutteryckOZéphirHSalleronJ. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Mult Scler. [Epub ahead of print].
7.
BozicCRichmanSPlavinaT. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1. Ann Neurol2011; 70: 742–750.
8.
WarnkeCRamanujamRPlavinaT. Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry2013; 84: 1199–1205.
9.
PlavinaTSubramanyamMBloomgrenG. Anti-JCV antibody index further defines PML risk in natalizumab-treated MS patients. The 27th Annual Meeting of the Consortium of Multiple Sclerosis Centers 2013. May 29 – June 1, 2013., Orlando, Florida, USA.
10.
WarnkeCvon GeldonGMarkwerthP. The CSF JCV antibody index for diagnosis of natalizumab-associated PML. Ann Neurol2014. Apr11. doi: 10.1002/ana.24153. [Epub ahead of print].
